265107-43-5

Basic information

• Product Name: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone
• Synonyms: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone;1-(6-Morpholinopyridin-3-yl)ethanone
• CAS NO: 265107-43-5
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.25
• Product Categories: pharmacetical
• Mol File: 265107-43-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 408.302°C at 760 mmHg
• Flash Point: 200.734°C
• Appearance: /
• Density: 1.162g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: 2-8°C
• PKA: 3.40±0.10(Predicted)
• CAS DataBase Reference: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(265107-43-5)
• EPA Substance Registry System: 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone(265107-43-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 265107-43-5(Hazardous Substances Data)

Usage

General Description

1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone, also known as MPYE, is a chemical compound containing a pyridine ring and a morpholine ring attached to an ethanone group. It is a heterocyclic compound with potential biological and pharmaceutical applications. MPYE has been studied as a potential inhibitor of protein kinases, which play crucial roles in various cellular processes and are implicated in diseases such as cancer. 1-[6-(Morpholin-4-yl)pyridin-3-yl]ethanone may also have other pharmacological activities, although further research is needed to fully understand its potential uses. MPYE's chemical structure and properties make it a promising candidate for drug development and other applications in the field of medicinal chemistry.

InChI:InChI=1/C11H14N2O2/c1-9(14)10-2-3-11(12-8-10)13-4-6-15-7-5-13/h2-3,8H,4-7H2,1H3

Upstream product

• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 200064-11-5 5-bromo-2-(4-morpholinyl)pyridine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 110-91-8 morpholine 
• 55676-22-7 3-acetyl-6-chloropyridine 
• 139042-59-4 1-(6-bromopyridin-3-yl)ethanone 
• 923034-23-5 dimethyl 2-(6-chloronicotinoyl)malonate 

Downstream Products

• 1026726-45-3 6-amino-4-(cyclohexyl-methyl-amino)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 1182181-38-9 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine 
• 214697-26-4 4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine 
• 328899-62-3 6-Amino-4-((3S,5R)-3,5-dimethyl-cyclohexyl)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328527-32-8 6-amino-4-[1-(2-bromo-phenyl)-ethyl]-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328527-30-6 6-amino-4-(2-bromo-benzyl)-6'-morpholin-4-yl-[2,3']bipyridinyl-5-carbonitrile 
• 328527-11-3 2-amino-4-(3-bromophenyl)-6-[2-(4-morpholinyl)-5-pyridyl]nicotinonitrile 

Relevant articles and documents

Design of adenosine kinase inhibitors from the NMR-based screening of fragments

A strategy is described for designing high-affinity ligands using information derived from the NMR-based screening of fragments. The method involves the fragmentation of an existing lead molecule, identification of suitable replacements for the fragments, and incorporation of the newly identified fragments into the original scaffold. Using this technique, novel substituents were rapidly identified and incorporated into lead inhibitors of adenosine kinase that exhibited potent in vitro and in vivo activities. This approach is a valuable strategy for modifying existing leads to improve their potency, bioavailability, or toxicity profile and thus represents a useful technique for lead optimization.

Compound capable of effectively inhibiting or killing multi-drug resistant bacteria and preparation method and application of compound

The invention discloses a compound capable of effectively inhibiting or killing bacterial microorganisms. The compound has a structural general formula shown as the formula I (please see the formula in the description). Pharmacodynamic experiments prove that the compound can effectively inhibit or kill the broad-spectrum and multi-drug resistant staphylococcus aureus, streptococcus pneumoniae and staphylococcus aureus and is expected to be developed into a novel effective antibacterial drug with new targets.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.